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Abstract
Background: Pancreatic surgery is complex with the potential for costly hospitalization.
Methods: A retrospective review of patients undergoing a pancreatic resection was performed.
Results: The median age of the study population was 64 years. Half of the cohort was female (51%), and
the majority were white (62%). Most patients underwent a pancreaticoduodenectomy (PD) (69%). The
pre-operative age-adjusted Charlson comorbidity index was zero for 36% (n = 50), 1 for 31% (n = 43) and
≥2 for 33% (n = 45). The Clavien–Dindo grading system for post-operative complication was grade I in
17% (n = 24), whereas 45% (n = 62) were higher grades. The medians direct fixed, direct variable, fixed
indirect and total costs were $2476, $15 397, $13 207 and $31 631, respectively. There was a positive
contribution margin of $7108, whereas the net margin was a loss of $6790. On univariate analyses, age,
type of operation and complication grade were associated with total cost (P ≤ 0.05), whereas operation
type and complication grade were associated with a net margin (P = 0.01). These findings remained
significant on multivariate analysis (P < 0.05).
Conclusions: Increased cost, reimbursement and revenue were associated with type of operation and
post-operative complications.
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Introduction
The United States of America has the most expensive healthcare
delivery system in the world.1 A significant portion of this cost
(29%) is spent on the care of surgical patients. Surgery cost is
expected to reach $912 billion/year, 7.3% of the US GDP, by 2025.2
In response to rising health care costs, the Affordable Care Act has
placed significant emphasis on cost control including the devel-
opment of bundled payment systems led by the Center for Medi-
care and Medicaid Innovation.3,4 In spite of the emphasis on cost
control, there is little data on the factors associated with the cost,
reimbursement and revenue for complex surgical procedures. In
this context, investigating pancreatic surgical procedures, in terms
of cost factors, may provide some insights.5–8
Limited data exist describing the interaction between costs,
charges and reimbursement involved inpancreatic surgery.Most of
the earlier reports, investigating the expenses related to pancreatic
surgery, report charges. However, this is an inaccurate representa-
tion of hospital financials, because charges do not reflect actual
costs and can significantly vary between institutions.9,10 Current
literature provides information on total costs associated with pan-
creatic surgery;11–13 however, there is sparse data showing the cost
breakdown and even fewer data on reimbursement and revenue.
The cost of pancreatic surgery has been found to be associated
with complications, surgeon experience, post-operative pathways,
volume and type of operation. For example, post-operative com-
plications have been found to be consistently associated with
increased hospital costs.8,14,15 In contrast, factors associated with
decreased costs include hospital volume,15 clinical pathways16 and
surgeon experience.17
Although Vollmer reported significant programmatic
revenue for a high-volume programme, he did not describe the
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relationship between clinical factors and revenue.18 To the best of
our knowledge, we report here the first study to examine the
association between clinical factors and revenue in patients under-
going a pancreatic resection. Given the limited data in the litera-
ture on cost, reimbursement and revenue for patients undergoing
a major pancreatic resection, we sought better definitions of these
factors.We studied patients in a prospective database from a high-
volume tertiary teaching hospital. The objective of the study was
to investigate whether there is any association of patients and
provider characteristics with cost of hospital care.
Methods
Data source and collection
A retrospective chart review was performed identifying all
patients who underwent pancreatic surgery between 2008 and
2012 at Vidant Medical Center (VMC), Greenville, North Caro-
lina. Patients who underwent pancreatic surgery for both non-
malignant and malignant processes were included. Patient
demographics, operative factors and financial data were obtained.
Patient demographics included age, gender, ethnicity, body mass
index (BMI), history of tobacco use and comorbidities. The age-
adjusted Charlson comorbidity index (ACCI) was calculated for
each patient. Operative factors included type of surgery
[pancreaticoduodenectomy (PD) or distal pancreatectomy sple-
nectomy (DPS)], operating surgeon, length of stay (LOS),
post-operative complications and discharge destination. The
Clavien–Dindo grading system was used to classify surgical com-
plications.19 The cost variables, including direct fixed cost, direct
variable cost, indirect fixed cost and total cost (defined below),
were obtained for each patient from Allscripts EPSi software
(Allscript, Raleigh, NC, USA). Cost only includes those accrued at
index admission (both pre- and post-operatively). Readmission
data are not included. Hospital reimbursement data were only
available for Medicare patients.
ACCI is a scoring method for comorbid conditions described
by Charlson,20 with additional points added for every decade over
40 years of age.21 The Clavien–Dindo grading system classifies
post-operative complications as degree of complication from I–V
and the level of therapy required in managing the complication. A
grade I complication is defined as any deviation from the normal
post-operative course, not requiring any interventions. Grade II
and grade III complications require either pharmacological or
procedural interventions, respectively. Grade IV complication are
life-threatening complications, while patient death is assigned as
grade V.5
Direct costs are the expenses directly related to patient care.
Direct fixed costs are non-variable expenses inherent to running a
functioning hospital (i.e. buildings, salaries and equipment).Vari-
able direct costs are those that vary with patient activity (i.e.
medications, medical tests or surgical equipment). Indirect costs
are expenses not directly related to patient care, but associated
with non-revenue producing areas of the hospital (i.e. financial
services department and informational technology).22,23 Total
costs are the sum total of direct fixed costs, direct variable cost and
indirect cost. The contribution margin is the reimbursement
minus the direct costs. Net margin is the contribution margin
minus indirect costs.
Statistical analysis
Patient demographic, operative and financial variables are repre-
sented as mean, median and/or percentage as necessary. Student’s
t-test or χ2-test were used to perform univariate analyses where
appropriate. Variables with a P ≤ 0.20 on univariate analysis were
included in logistic regression models. A value of P ≤ 0.05 was
defined as statistically significant. Analysis was conducted using
JMP® Pro version 10.0.0; 2012 (SAS Institute Inc., Cary, NC,
USA).
Results
Patient population
In the period between 2008 and 2012, 138 patients met the inclu-
sion criteria. Table 1 summarizes the characteristics of the study
population. The mean and median ages of the patient population
were 63 ± 12.8 and 64 years (range 17–90), respectively. Patients
were divided based on age into the following groups: <50 (n = 18,
13%), 50–59 (n = 32, 23%), 60–69 (n = 42, 30%), 70–79 (n = 30,
22%) and ≥80 years (n = 16, 12%). The majority of the patients
were female (51%), white (62%) and smokers (57%). The mean
and median BMI were 28 ± 6.5 and 28 kg/m2 (range 12–49),
respectively. There was a nearly equal representation of patients in
each of the ACCI categories: 0 (36%), 1 (31%) and ≥2 (33%).
Table 1 Cost and revenue for patients undergoing pancreatic surgery, 2008–2012
Cost variable Range (in $) Median (in $) Mean ± SD (in $)
Direct Fixed 543–16 080 2 476 3 205 ± 2 467
Direct Variable 3 944–169 431 15 397 21 198 ± 22 759
Fixed Indirect 3 365–133 591 13 207 18 467 ± 17 376
Total Cost 8 487–319 102 31 631 42 869 ± 42 218
Contribution Margina 45 024–71 592 7 108 7 350 ± 14 380
Net Margina 161 040–32 168 (6 790) (11 467) ± 25 843
aFor Medicare patients only.
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A PD was performed in 95 patients (69%), whereas a DPS was
performed in the remaining 43 patients (31%). One surgeon
(attending ‘A’) performed 38 operations (28%), whereas a second
surgeon (attending ‘B’) performed 83 operations (60%); the
remaining 17 operations (12%) were performed by six other sur-
geons. Although no post-operative complications were observed
in 52 patients (38%), the remaining 86 patients (62%) had a
Clavien–Dindo grade I or greater post-operative complication. To
follow are the numbers of patients found with different grades of
complication: 24 patients (17%) with a grade I complication, 49
patients (36%) with a grade II complication, 3 patients (2%) with
a grade IV complication and 10 patients (7%) with a grade V
complication. The mean and median LOS was 16 and 11 days
(range 1–100), respectively. The majority of patients, n = 101
(73%), were discharged home with 19 (19%) patients requiring
home health care. Ninety-six patients (70%) were Medicare and
Medicaid patients. Reimbursement data were available for 77
(80%) Medicare patients.
Hospital cost for the entire population and margins
for medicare patients
Table 1 presents the medians of different hospital costs for the
entire study population. The median direct fixed cost was $2476
(range $543 – $16 080), whereas the median direct variable cost,
median total direct cost and median indirect cost were $15 397
(range $3944–$169 431), $18 268 (range $4548–$185 511) and
$13 207 (range $3365–$133 591), respectively. The median total
cost was $31 631 (range $8487–$319 102). The median contribu-
tion margin and net margin were $7108 (range –$42 024–
$71 592) and –$6790 (range –$161 040–$32 168), respectively.
Univariate analysis
Univariate analysis revealed significant associations of provider,
type of operation and Clavien–Dindo grade of complication with
fixed and variable direct hospital costs. However, indirect hospital
costs are significantly associated with only type of operation and
grade of complication (P < 0.0001) with (Table 2). None of the
factors were significantly associated with contribution margin,
whereas type of operation and grade of complication were signifi-
cantly associated with net hospital margin (P = 0.01) (Table 3).
Multivariate analysis
On logistic regression analysis, increased direct fixed hospital cost
was found to be independently associated with age of the patient
≥80 years [odds ratio (OR): 4.87, P = 0.05] and post-operative
complications greater than grade I (OR: 5.00, P = 0.0001). We
found increased direct variable hospital cost to be associated with
operative complications greater than a grade I (OR: 5.19, P =
0.0001) and pancreaticoduodenectomy (OR: 3.88, P = 0.003). In
contrast, grade I (OR: 3.98, P = 0.02) or greater (OR: 6.95, P ≤
0.0001) post-operative complications and PD (OR: 4.69, P =
0.0006) were significantly associated with a higher indirect hospi-
tal cost. An increased total hospital cost of care remained indepen-
dently associated with increasing age (P ≤ 0.04), grade I (OR: 3.20,
P = 0.04) or greater (OR: 6.65, P < 0.0001) post-operative com-
plication, and PD (OR: 3.73, P = 0.004) (Table 4). Multivariate
analysis, that included all factors with a P ≤ 0.20 on univariate,
showed an increased net margin to be significantly associated with
a distal pancreatectomy (OR: 5.06, P = 0.01) and patients with no
post-operative complications (OR: 3.81, P = 0.02) (Table 5).
Discussion
Pressure to curtail healthcare expenditure together with the
looming implementation of bundled payments makes it impera-
tive that surgeons understand the cost of care and potential impli-
cations on the dynamics of hospital finance.4 In this study, we
found that increased hospital cost was associated with advanced
age, complications and type of pancreatic surgery; however, only
complications and type of operation were found to be associated
with hospital reimbursement. Although our pancreatic pro-
gramme had a positive hospital contribution margin, the pro-
grammatic net hospital margin was a negative $6790 per patient.
Total hospital cost (direct plus indirect cost) was independently
associated with patient age, complications and type of operation.
The above findings are consistent with previous reports.11,12
Wilson and Lightwood also found that older patients had greater
total medical care costs for pancreatic surgery.24 In addition,
multiple investigators have demonstrated that total costs increase
with complications.11–13,25 We found that a PD was associated with
a significantly increased total cost. Given the complex nature of a
PD in comparison with a distal pancreatectomy, this finding is not
unexpected. However, there are surprisingly very little data
directly comparing the cost between a PD and distal pancreatec-
tomy. Cecka found that a greater number and severity of compli-
cations were associated with an increased cost of care, but no
difference in costs was found when comparing a PD and distal
pancreatectomy.7 In contrast, Pratt reported an increase in the cost
for a PD compared with a distal pancreatectomy.26
Direct costs or those costs, directly related in providing medical
care to a specific patient,18 are thought to be a more accurate
representation of true cost. Trends are similar to those associated
with the total cost of care. We found that direct costs were also
associated with increased complications and type of operation.
The median direct cost was $18 268, ranging from $4548 to
$185 511. Although Enestvedt and colleagues described a greater
median direct cost of $30 937, they also identified a range in costs
based on complications, for example, patients with major compli-
cations had a median cost of $56 224 versus $29 038 for those
without a complication (P < 0.001).27
Direct costs can be further divided into fixed and variable costs.
Fixed direct costs are set costs related to a hospital’s basic function
(i.e. physical plant, salaries, and equipment). Variable direct costs
are those that vary with patient activity such as medications,
medical tests or surgical equipment.22,23 In order to better assess
how patient care for pancreatic surgery specifically affects the
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direct cost of care, we performed a separate cost analysis for fixed
and variable direct costs. As expected, variable direct costs
increased with complications and type of operation. Other inves-
tigators have also reported a higher variable direct cost for patients
with complications after a pancreaticoduodenectomy;25,27 factors
that contributed to this increase were radiological tests, medica-
tions, laboratory tests and inpatient bed use.25 To the best of our
knowledge, the present study is the first to report the association
of fixed direct costs with pancreatic surgery. We identified that
elderly patients and those with complications had the highest
direct fixed cost of care. In our patient population, the increase in
the fixed cost for elderly patients and those with complications
may be secondary to an increase in the LOS resulting in a greater
allocation of direct fixed costs.22
Indirect costs are those not directly related to individual patient
care, but are associated with the non-revenue-producing areas of
the hospital such as administration, financial services department
and information technology.23 As mentioned before, most of the
previous studies assessing the cost for pancreatic surgery focus
either on the total cost or direct cost of care, with no specific
analysis related to the indirect costs. We found, interestingly, that
both complications and a more complex surgery (PD versus DPS)
also increased indirect costs. Therefore, patients who had compli-
cations not only had an increased cost of care related specifically
to providing care for these complications, but also had to bear
indirect hospital costs. Although the exact nature of indirect cost
is somewhat ethereal, this additional cost (about 50% of the total
cost) profoundly impacts the net margin.
Table 2 Univariate analysis of factors associated with direct, indirect and total cost for patients undergoing a pancreatic resection,
2008–2012
Total Direct fixed Direct variable Fixed indirect Total Cost
≥2500 <2500 P ≥15400 <15400 P >13200 ≤13200 P >32000 <32000 P
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
68 70 69 69 69 69 67 71
Age <50 5 (27.8) 13 (72.2) 0.14 6 (33.3) 12 (66.7) 0.12 5 (27.8) 13 (72.2) 0.06 3 (16.7) 15 (83.3) 0.008
50–59 16 (50) 16 (50) 17 (53.1) 15 (46.9) 18 (56.3) 14 (43.7) 18 (56.3) 14 (43.7)
60–69 19 (45.2) 23 (54.8) 17 (40.5) 25 (59.5) 17 (40.5) 25 (59.5) 17 (40.5) 25 (59.5)
70–79 17 (56.7) 13 (43.3) 20 (66.7) 10 (33.3) 19 (63.3) 11 (36.7) 19 (63.3) 11 (36.7)
>= 80 11 (68.8) 5 (31.2) 9 (56.3) 7 (43.7) 10 (62.5) 6 (37.5) 10 (62.5) 6 (37.5)
Gender 0.50 0.86 0.39 0.62
Male 35 (52.2) 32 (47.8) 34 (50.8) 33 (49.2) 36 (53.7) 31 (46.3) 34 (50.8) 33 (49.2)
Race White 40 (47.1) 45 (52.9) 0.67 42 (49.4) 43 (50.6) 0.32 43 (50.6) 42 (49.4) 0.86 43 (50.6) 42 (49.4) 0.39
AA 26 (54.2) 22 (45.8) 26 (54.2) 22 (45.8) 23 (47.9) 25 (52.1) 23 (47.3) 25 (52.1)
Other 2 (40) 3 (60) 1 (20) 4 (80) 3 (6) 2 (40) 1 (20) 4 (80)
BMI 0.95 0.80 0.68 0.67
Mean 28.0 28.0 28.2 27.9 28.3 27.8 28.4 27.8
Smoking Yes 37 (46.8) 42 (53.2) 0.51 38 (48.1) 41 (51.9) 0.61 35 (44.3) 44 (55.7) 0.12 35 (44.3) 44 (55.7) 0.25
No 31 (52.5) 28 (47.5) 31 (52.5) 28 (47.5) 34 (57.6) 25 (42.4) 32 (54.2) 27 (45.8)
Provider A 25 (65.8) 13 (34.2) 0.04 26 (68.4) 12 (31.6) 0.02 23 (60.5) 15 (39.5) 0.31 23 (60.5) 15 (39.5) 0.21
B 37 (44.6) 46 (55.4) 35 (42.2) 48 (57.8) 38 (45.8) 45 (54.2) 36 (43.4) 47 (56.6)
Other 6 (35.3) 11 (64.7) 8 (47.1) 9 (52.9) 8 (47.1) 9 (52.9) 8 (47.1) 9 (52.9)
Operation Whipple 54 (56.8) 41 (43.2) 0.008 57 (60) 38 (40) 0.0004 58 (61.1) 37 (39.0) 56 (59.0) 39 (41.0)
DP 14 (32.6) 29 (67.4) 12 (27.9) 31 (72.1) 11 (25.6) 32 (74.4) 11 (25.6) 32 (74.4)
ACCI 0 22 (44) 28 (56) 0.63 25 (50) 25 (50) 0.98 25 (50) 25 (50) 0.98 23 (46) 27 (54) 0.88
1 23 (53.5) 20 (46.5) 22 (51.2) 21 (48.8) 21 (48.8) 22 (51.2) 21 (48.8) 22 (51.2)
≥2 23 (51.1) 22 (48.9) 22 (48.9) 23 (51.1) 23 (51.1) 22 (48.9) 23 (51.1) 22 (48.9)
C–D 0 14 (26.9) 38 (73.1) <0.001 16 (30.8) 36 (69.2) <0.001 13 (25) 39 (75) <0.001 13 (25) 39 (75) <0.001
Grade I 12 (50.0) 12 (50.0) 9 (37.5) 15 (62.5) 12 (50) 12 (50) 11 (45.8) 13 (54.2)
>I 42 (67.7) 20 (32.3) 44 (71.0) 18 (29.0) 44 (71.0) 18 (29.0) 43 (69.4) 19 (30.7)
AA, African American; BMI, body mass index; DP, distal pancreatectomy; ACCI, age-adjusted Charlson Comorbidity Index; C-D, Clavien–Dindo.
HPB 2015, 17, 311–317
314 HPB
© 2014 International Hepato-Pancreato-Biliary Association
Table 3 Factors associated with various median re-imbursement: univariate analysis
Total Contribution margin Net margin
≥6175 <6175 P-value ≥ (6512) < (6512) P-value
N (%) N (%) N (%) N (%)
48 (50.0) 48 (50.0) 48 (50.0) 48 (50.0)
Age by decade <50 0 0 0.70 0 0 0.69
50–59 2 (50.0) 2 (50.0) 3 (75.0) 1 (25.0)
60–69 12 (42.9) 16 (57.1) 15 (53.6) 13 (46.4)
70–79 17 (58.6) 12 (41.4) 14 (48.3) 15 (51.7)
≥80 8 (50) 8 (50) 7 (43.8) 9 (56.3)
Gender Male 21 (55.3) 17 (44.7) 0.42 21 (55.3) 17 (44.7) 0.42
Race White 25 (50.0) 25 (50.0) 0.47 24 (48.0) 26 (52.0) 0.45
AA 14 (53.9) 12 (46.1) 14 (53.9) 12 (46.2)
Other 0 1 (100.0) 1 (100.0) 0
BMI Mean 26.9 ± 5.97 27.4 ± 5.64 0.70 27.3 ± 5.62 27.0 ± 5.99 0.81
Smoking Yes 23 (52.3) 21 (47.7) 0.74 21 (47.7) 22 (52.3) 0.55
No 16 (48.5) 17 (51.5) 18 (54.6) 15 (45.4)
Provider A 6 (33.3) 12 (66.7) 0.24 7 (38.9) 11 (61.1) 0.20
B 28 (56.0) 22 (44.0) 29 (58.0) 21 (42.0)
Other 5 (55.6) 4 (44.4) 3 (33.3) 6 (66.7)
Operation Whipple 30 (52.6) 27 (47.4) 0.56 24 (42.1) 33 (57.9) 0.01
DP 9 (45.0) 11 (55.0) 15 (75.0) 5 (25.0)
ACCI 0 12 (50.0) 12 (50.0) 0.92 10 (41.7) 14 (58.3) 0.23
1 11 (47.8) 12 (52.2) 15 (65.2) 8 (34.8)
≥2 16 (53.3) 14 (46.7) 14 (46.7) 16 (53.3)
C–D Grade 0 16 (51.6) 15 (48.4) 0.96 22 (71.0) 9 (29.0) 0.01
I 6 (50.0) 6 (50.0) 5 (41.7) 7 (58.3)
>I 17 (50.0) 17 (50.0) 12 (35.3) 22 (64.7)
AA, African American; BMI, body mass index; DP, distal pancreatectomy; ACCI, Age-adjusted Charlson Comorbidity Index; C–D, Clavien-Dindo.
Table 4 Factors associated with increased cost for each of the various cost variables: logistic regression
Variables Direct fixed cost Direct variable cost Indirect cost Total cost
OR P OR P OR P OR P
Age <50 (Ref) 1 1 1 1
50–59 2.4 (0.6–9.8) 0.20 1.8 (0.5–7.2) 0.40 3.6 (0.9–16.8) 0.08 7.0 (1.6–39.2) 0.009
60–69 2.0 (0.6–7.8) 0.30 0.9 (0.2–3.5) 0.86 1.5 (0.4–6.5) 0.60 3.3 (0.8–17.7) 0.11
70–79 3.0 (0.8–12.6) 0.11 2.9 (0.7–12.4) 0.14 4.0 (0.9–19.4) 0.06 8.5 (1.9–49.0) 0.005
≥80 4.9 (1.0–26.8) 0.05 1.6 (0.3–8.6) 0.57 2.1 (0.4–12.2) 0.41 5.9 (1.1–39.3) 0.04
Provider Other (Ref) 1 1 – – – –
Attending B 1.0 (0.3–3.7) 0.96 0.5 (0.1–1.9) 0.33 – – – –
Attending A 2.8 (0.7–11.4) 0.14 2.1 (0.5–8.5) 0.31 – – – –
C–D Grade 0 (Ref) 1 1 1 1
I 2.7 (0.9–8.0) 0.08 1.2 (0.4–3.7) 0.81 4.0 (1.3–13.2) 0.02 3.2 (1.0–10.3) 0.04
>I 5.0 (2.2–12.1) <0.001 5.2 (2.2–13.0) 0.0001 7.0 (2.9–17.9) <0.0001 6.7 (2.8–16.9) <0.0001
Operation DP (Ref) 1 1 1 1
Whipple 2.1 (0.9–5.0) 0.09 3.3 (1.6–10.4) 0.003 4.7 (1.9–12.4) 0.0006 3.3 (1.5–9.7) 0.004
OR, odds ratio; DP, distal pancreatectomy; C–D, Clavien–Dindo.
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As mentioned earlier, the net margin is calculated by subtract-
ing the total cost (direct and indirect) from reimbursement. Reim-
bursement is the actual payment received from the payer; in this
study we have data only for the Medicare patients. Contribution
margin (gross profit) can also be calculated by subtracting the direct
costs from reimbursement.18 We found the median contribution
margin per patient to be $7108.However, when indirect costs were
included for patients with Medicare, we found a loss of $6790 per
patient.One must be mindful that the indirect costs may be variable
across institutions as a result of local management patterns. Vollmer
also described a similar dramatic effect of indirect costs in their
pancreatic programme, a decrease in the contribution margin;
after factoring in indirect costs, the contribution margin of $6
million was decreased by $4 million dollars to a net margin of $2
million per year.18
There are inherent limitations to our data because of its retro-
spective nature. Reimbursement data were only available for
Medicare patients. As a result of the lack of reimbursement data
for patients with private insurance (28%), our findings do not
reflect the overall programme margins. In addition, the data also
lacked readmission costs and costs related to the non-surgical care
and work-up of these patients, all of which might have a signifi-
cant effect on both costs and revenue.
Based on the above findings, we conclude that complex gastro-
intestinal surgeries such as pancreatic resections are intricate both
medically and financially. Components of hospital cost and
revenue include direct costs (fixed and variable), indirect costs,
contribution margin and net margin. Factors associated with
increased hospital cost included patient age, type of operation and
post-operative complications. For Medicare patients, who under-
went pancreatic surgery, the hospital had a net negative margin of
$6790 per patient. In order to minimize loss or sustain a pancre-
atic programme at Medicare rates, efforts must be directed in
preventing or mitigating post-operative complications.
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